Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma. 
No comment yet.
Sign up to comment
Scoop.it!
BigField GEG Tech's insight:
At a time when PD-1 inhibitors are dominating the immunotherapy field, a team of researchers is seeking to use groundbreaking CRISPR gene editing technology for the first time in human beings to create an engineered T-cell agent that would knock out the gene that controls the immune checkpoint’s activity.
|
Scoop.it!
BigField GEG Tech's insight:
On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical trial at the West China Hospital, also in Chengdu. The researchers removed immune cells from the recipient’s blood and then disabled a gene in them using CRISPR–Cas9, which combines a DNA-cutting enzyme with a molecular guide that can be programmed to tell the enzyme precisely where to cut. The disabled gene codes for the protein PD-1, which normally puts the brakes on a cell’s immune response: cancers take advantage of that function to proliferate.
Scoop.it!
BigField GEG Tech's insight:
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9. The researchers successfully edited CXCR4 and PD-1. Deep sequencing of a target site evaluated the knock-in genome modifications up to ∼20% of cells, which accounted for up to approximately one-third of total editing events.
|
CB-010, an allogeneic anti-CD19 CAR T-cell therapy with a PD-1 knockout, is being evaluated in the Phase 1 ANTLER trial (NCT04637763) in patients with relapsed/refractory NHL-B, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma. This therapy is a genome-editing strategy designed to improve the persistence of anti-tumor activity by limiting premature depletion of CAR-T cells. The first multicenter, open-label, Phase 1 human trial ANTLER is evaluating the safety and efficacy of CB-010 in patients with relapsed/refractory B-NHL who have received at least 2 prior lines of chemoimmunotherapy. The study consists of 2 parts, including the dose escalation part (Part A) and the dose expansion part (Part B). Results from the ANTLER trial presented at the EHA 2022 Congress demonstrated encouraging safety data and antitumor activity for CB-010 at dose level 1 (40 x 106 CAR T cells). Specifically, results indicated that all 6 patients achieved a complete response (CR) as the best response after treatment with CB-010 at dose level 1. At 6 months, 3 of 6 patients maintained a CR, with the longest duration being 15 months. The investigators are currently recruiting patients for the second dose level of 80 x 106 CAR T cells.